Pharmakea, Inc.

Lion Bioscience Ag

Panmira Pharmaceuticals, LLC

Brickell Biotech, Inc.

Kevin Ross Holme

Martin W Rowbottom

Brian Andrew Stearns

David Gregory Lonergan

Jason Edward Brittain

Timothy Gahman

Christopher David King

Karen J Watson-Straughan

Michael J Green

Yazhong Pei

Ronald R Tuttle

Beverly E Girten

Hengyuan Lang

Michael C Griffith

Sandra R Slivka

Christa Hamashin

Ming Qi

James E Macdonald

Douglas L Hitchin

Kevin C Dines

Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making

Described herein is the DPantagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4&#x2032;-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DPantagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D-dependent or prostaglandin D-mediated diseases or conditions.

DP2 antagonist and uses thereof

Triamine derivative melanocortin receptor ligands and methods of using same

Methods for treating sexual dysfunction, such as erectile dysfunction or sexual arousal disorder, with a compound having the generic formula X &mdash;X -(D)Phe-Arg-(D)Trp-X . A particularly useful compound is HP-228, which has the formula Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH . The invention also provides methods for selecting melanocortin receptor-3 ligands by determining whether a compound modulates the activity of MC-3 as an agonist or antagonist. These methods can be used to screen compound libraries for ligands to treat MC-3-associated conditions. Such conditions include sexual dysfunction, including erectile dysfunction and sexual arousal disorder.

Melanocortin receptor-3 ligands to treat sexual dysfunction

Growing community of inventors

San Diego, CA, United States of America

Kevin Ross Holme